Skip to main content

Correction to: The best drug supplement for obesity treatment: a systematic review and network meta-analysis

The Original Article was published on 18 October 2021

Correction to: Diabetol Metab Syndr (2021) 13:110 https://doi.org/10.1186/s13098-021-00733-5

Following publication of the original article [1], the Table 2 reports incorrect data for some of the studies included in the analysis:

  1. 1.

    In the study by Davies et al. (row 3), the dose of liraglutide should read 3.0 mg instead of 0.3 mg.

  2. 2.

    In the study by Greenway et al. (row 6), it should read Naltrexone 16.0 mg + bupropion instead of Naltrexone + bupropion 16.0 mg, and Naltrexone 32.0 mg + bupropion instead of Naltrexone + bupropion 32.0 mg.

  3. 3.

    In the study by O’Neil et al. (row 9) it should read Lorcaserin 10 mg BID instead of Orlistat 120.mg BID, and Lorcaserin 10 mg QD instead of Orlistat 120.mg QD.

The authors apologize for such mistakes. The data and the script files used in the analysis are available as Additional files 1, 2 and 3 to all readers.

Reference

  1. Salari N, Jafari S, Darvishi N, Valipour E, Mohammadi M, Mansouri K, Shohaimi S. The best drug supplement for obesity treatment: a systematic review and network meta-analysis. Diabetol Metab Syndr. 2021;13:110. https://doi.org/10.1186/s13098-021-00733-5.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Masoud Mohammadi.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

Input data.

Additional file 2.

Network meta analysis.

Additional file 3.

R script.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Salari, N., Jafari, S., Darvishi, N. et al. Correction to: The best drug supplement for obesity treatment: a systematic review and network meta-analysis. Diabetol Metab Syndr 14, 68 (2022). https://doi.org/10.1186/s13098-022-00838-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13098-022-00838-5